JOP20200222A1 - أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون - Google Patents
أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتونInfo
- Publication number
- JOP20200222A1 JOP20200222A1 JOP/2020/0222A JOP20200222A JOP20200222A1 JO P20200222 A1 JOP20200222 A1 JO P20200222A1 JO P20200222 A JOP20200222 A JO P20200222A JO P20200222 A1 JOP20200222 A1 JO P20200222A1
- Authority
- JO
- Jordan
- Prior art keywords
- bruton
- tyrosine kinase
- crystalline forms
- conditions
- kinase inhibitor
- Prior art date
Links
- 229940125814 BTK kinase inhibitor Drugs 0.000 title abstract 2
- 229940124291 BTK inhibitor Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 crystalline forms Chemical compound 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
يتعلق الاختراع الحالي عن مثبط إنزيم تيروسين كيناز لبروتون (Btk) 1- ((R)- 3- (4-فينوكسي فينيل)-1H- بيرازولول [3، 4-d] بيريميدين-1-يل)بيريميدين-1-يل)بيبريدين-1-يل)بروب-2- ين-1- أون، بما في ذلك صورة البلورية، وذواباته، وأملاحه المقبولة صيدلانياً. كما يتم الكشف عن تركيبات صيدلانية تشتمل على مثط Btk، وكذلك طرق لاستخدام مثبط Btk، سواء بمفرده أو بالاشتراك مع عوامل علاجية أخلى، في علاج أمراض أو حالات مناعة ذاتية، أو أمراض أو حالات مناعة غير متجانسة، أو سرطان، مثل الأورام الليمفاوية، وأمراض أو حالات التهابية.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261655381P | 2012-06-04 | 2012-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200222A1 true JOP20200222A1 (ar) | 2022-10-30 |
Family
ID=49712527
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2013/0168A JO3754B1 (ar) | 2012-06-04 | 2013-06-03 | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
JOP/2020/0222A JOP20200222A1 (ar) | 2012-06-04 | 2020-09-09 | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2013/0168A JO3754B1 (ar) | 2012-06-04 | 2013-06-03 | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
Country Status (32)
Country | Link |
---|---|
US (25) | US9296753B2 (ar) |
EP (1) | EP2854859A4 (ar) |
JP (8) | JP6236071B2 (ar) |
KR (7) | KR20220093389A (ar) |
CN (2) | CN104736178A (ar) |
AR (2) | AR092844A1 (ar) |
AU (6) | AU2013271918C1 (ar) |
BR (1) | BR112014030424A8 (ar) |
CA (4) | CA2991994C (ar) |
CL (3) | CL2014003306A1 (ar) |
CO (1) | CO7240408A2 (ar) |
CR (1) | CR20140558A (ar) |
DO (3) | DOP2014000274A (ar) |
EA (1) | EA201492082A1 (ar) |
EC (2) | ECSP14033163A (ar) |
GT (1) | GT201400281A (ar) |
HK (1) | HK1208803A1 (ar) |
IL (3) | IL235894B (ar) |
JO (2) | JO3754B1 (ar) |
MA (2) | MA41654B2 (ar) |
MX (2) | MX348290B (ar) |
MY (2) | MY194911A (ar) |
NZ (4) | NZ737725A (ar) |
PE (2) | PE20150174A1 (ar) |
PH (2) | PH12014502681A1 (ar) |
SG (2) | SG11201408067YA (ar) |
TN (1) | TN2014000492A1 (ar) |
TW (3) | TWI662963B (ar) |
UA (2) | UA114421C2 (ar) |
UY (2) | UY34848A (ar) |
WO (1) | WO2013184572A1 (ar) |
ZA (2) | ZA202105174B (ar) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101610676B (zh) | 2006-09-22 | 2013-03-27 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2010009342A2 (en) | 2008-07-16 | 2010-01-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
NZ702485A (en) | 2010-06-03 | 2016-04-29 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
SG10201600077RA (en) | 2011-01-11 | 2016-02-26 | Glaxosmithkline Llc | Combination |
EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
PT3409278T (pt) | 2011-07-21 | 2020-12-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de proteína cinase heterocíclicos |
PL2788343T3 (pl) | 2011-12-11 | 2018-10-31 | Viamet Pharmaceuticals (NC), Inc. | Związki inhibitora metaloenzymu |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
CA2991994C (en) | 2012-06-04 | 2022-06-28 | Pharmacyclics Llc | Pharmaceutical formulation for oral administration comprising ibrutinib |
CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
EP2914263A4 (en) * | 2012-11-02 | 2016-04-27 | Pharmacyclics Inc | ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR |
CA2890934A1 (en) | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
KR102334260B1 (ko) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 및 alk2 억제제 및 이들의 사용 방법 |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
KR20230047203A (ko) | 2013-08-22 | 2023-04-06 | 반다 파마슈티칼즈, 인코퍼레이티드. | 암 치료 |
CN105764896A (zh) | 2013-09-30 | 2016-07-13 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶的抑制剂 |
WO2015054612A1 (en) * | 2013-10-11 | 2015-04-16 | University Of Massachusetts | Treating organ-specific t cell mediated autoimmune diseases |
EP4115886A1 (en) | 2013-10-25 | 2023-01-11 | Pharmacyclics LLC | Methods of treating and preventing graft versus host disease |
WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
CN103694241A (zh) * | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
US10272083B2 (en) * | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
CN106008516A (zh) * | 2014-01-29 | 2016-10-12 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
CA2942204A1 (en) * | 2014-03-12 | 2015-09-17 | Novartis Ag | Combination comprising a btk inhibitor and an akt inhibitor |
JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼcガンマ2及び耐性に関連した変異 |
AU2015237744A1 (en) * | 2014-03-27 | 2016-09-15 | Wavelength Enterprises Ltd | Ibrutinib solid forms and production process therefor |
CN105085529A (zh) * | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
US20160008366A1 (en) * | 2014-07-14 | 2016-01-14 | Pharmacyclics Llc | Btk inhibitors for the treatment of cns malignancies |
SG11201700774UA (en) * | 2014-08-01 | 2017-02-27 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
US9533991B2 (en) | 2014-08-01 | 2017-01-03 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
JP2017523206A (ja) * | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
MX2017001656A (es) * | 2014-08-08 | 2017-07-24 | Pharmacyclics Llc | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. |
EP3180343A1 (en) | 2014-08-14 | 2017-06-21 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
WO2016050422A1 (en) * | 2014-10-01 | 2016-04-07 | Ratiopharm Gmbh | Acid addition salt of ibrutinib |
WO2016079216A1 (en) | 2014-11-20 | 2016-05-26 | Sandoz Ag | Physical forms of ibrutinib, a bruton's kinase inhibitor |
ES2667247T3 (es) * | 2015-01-30 | 2018-05-10 | Taiho Pharmaceutical Co., Ltd. | Sal novedosa de compuesto de pirimidina condensado y cristal del mismo |
CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
PT3265084T (pt) * | 2015-03-03 | 2024-02-13 | Pharmacyclics Llc | Formulações farmacêuticas de inibidor de tirosina cinase de bruton |
JP2018511580A (ja) * | 2015-03-03 | 2018-04-26 | ドクター レディズ ラボラトリーズ リミテッド | イブルチニブの多形体 |
WO2016150349A1 (zh) * | 2015-03-20 | 2016-09-29 | 苏州晶云药物科技有限公司 | 一种pci-32765晶型a的制备方法 |
MA41828A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
MA41827A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
US10377758B2 (en) | 2015-04-02 | 2019-08-13 | Ratiopharm Gmbh | Co-crystals of ibrutinib with carboxylic acids |
SG11201707989PA (en) * | 2015-04-06 | 2017-10-30 | Janssen Pharmaceutica Nv | Compositions containing ibrutinib |
CN106153797B (zh) * | 2015-04-20 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种依鲁替尼及依鲁替尼制剂有关物质分析方法 |
CN106153798B (zh) * | 2015-04-22 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种用于分析依鲁替尼及依鲁替尼制剂有关物质的hplc方法以及这些杂质做参比标准的用途 |
CZ2015442A3 (cs) * | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Ibrutinib hemisulfát |
WO2016207172A1 (en) * | 2015-06-26 | 2016-12-29 | Sandoz Gmbh | Preparation of pure amorphous ibrutinib |
WO2017011314A1 (en) * | 2015-07-10 | 2017-01-19 | Paharmacyclics Llc | Btk and hdac combinations |
EP3337485B1 (en) | 2015-08-19 | 2021-03-17 | Sun Pharmaceutical Industries Ltd | Crystalline forms of ibrutinib |
EA038214B1 (ru) | 2015-09-18 | 2021-07-23 | Майковиа Фармасьютикалс, Инк. | Способ получения противогрибковых соединений |
US9834561B2 (en) * | 2015-10-28 | 2017-12-05 | Scinopharm Taiwan, Ltd. | Process for preparing ibrutinib and its intermediates |
ITUB20155616A1 (it) * | 2015-11-16 | 2017-05-16 | Laboratorio Chimico Int S P A | Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina. |
CN105294696A (zh) * | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
WO2017096331A1 (en) | 2015-12-04 | 2017-06-08 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
CN105622614B (zh) * | 2015-12-18 | 2021-02-26 | 重庆医药工业研究院有限责任公司 | 一种依鲁替尼无定型物及其制备方法 |
CN106905320A (zh) * | 2015-12-23 | 2017-06-30 | 杭州容立医药科技有限公司 | 一种适合药用的依鲁替尼及其制剂 |
CA3008338A1 (en) * | 2016-01-19 | 2017-07-27 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
EA201891664A1 (ru) * | 2016-01-19 | 2019-02-28 | Янссен Фармацевтика Нв | Составы/композиции, содержащие ингибитор btk |
CN106995445B (zh) * | 2016-01-22 | 2021-08-03 | 山东新时代药业有限公司 | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 |
MX2018008549A (es) * | 2016-01-27 | 2018-09-19 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica que comprende derivado de quinolina o sal del mismo. |
WO2017134684A2 (en) | 2016-02-01 | 2017-08-10 | Natco Pharma Limited | An improved process for the preparation of ibrutinib |
US10435409B2 (en) | 2016-02-04 | 2019-10-08 | Shilpa Medicare Limited | Process for the preparation of ibrutinib |
GB2558514A (en) * | 2016-02-09 | 2018-07-18 | Azad Pharmaceutical Ingredients Ag | Process for the synthesis of stable amorphous ibrutinib |
CN105646498A (zh) * | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型f及制备方法 |
CN107286163A (zh) * | 2016-03-30 | 2017-10-24 | 上海星泰医药科技有限公司 | 一种依鲁替尼的新晶型及其制备方法 |
CZ2016196A3 (cs) | 2016-04-06 | 2017-10-18 | Zentiva, K.S. | Pevné formy Ibrutinibu |
CZ2016276A3 (cs) | 2016-05-11 | 2017-11-22 | Zentiva, K.S. | Pevné formy volné báze ibrutinibu |
US20180228749A1 (en) * | 2016-06-28 | 2018-08-16 | Mehmet Nevzat Pisak | Surfactants and compositions for treatment of viral skin conditions |
CA3028169A1 (en) * | 2016-06-29 | 2018-01-04 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
CN106117214A (zh) * | 2016-06-29 | 2016-11-16 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
MA46783A (fr) | 2016-11-03 | 2019-09-11 | Juno Therapeutics Inc | Polythérapie de type thérapie cellulaire t et inhibiteur de btk |
US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
CN108653231A (zh) * | 2017-04-01 | 2018-10-16 | 北京赛林泰医药技术有限公司 | 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法 |
AU2018275891A1 (en) | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
US20220225597A1 (en) | 2017-06-29 | 2022-07-21 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
JP7190452B2 (ja) | 2017-07-04 | 2022-12-15 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 医薬組成物及びその製造方法 |
MA50057A (fr) | 2017-09-01 | 2020-07-08 | Juno Therapeutics Inc | Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire |
US20200268761A1 (en) | 2017-09-19 | 2020-08-27 | Cipla Limited | Compositions comprising ibrutinib and an alkaloid having enhanced bioavailability |
WO2019070698A1 (en) | 2017-10-02 | 2019-04-11 | Johnson Matthey Public Limited Company | NEW FORMS OF IBRUTINIB |
US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
US11576917B2 (en) | 2018-01-20 | 2023-02-14 | Natco Pharma Limited | Pharmaceutical compositions comprising Ibrutinib |
WO2019195753A1 (en) | 2018-04-05 | 2019-10-10 | Tolero Pharmaceuticals, Inc. | Axl kinase inhibitors and use of the same |
WO2019195827A1 (en) | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤 |
WO2019211870A1 (en) | 2018-05-02 | 2019-11-07 | Cipla Limited | Polymorphic forms of ibrutinib |
CN112584902A (zh) | 2018-05-03 | 2021-03-30 | 朱诺治疗学股份有限公司 | 嵌合抗原受体(car)t细胞疗法和激酶抑制剂的组合疗法 |
EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
RU2711106C2 (ru) * | 2018-06-06 | 2020-01-15 | Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" | Кристаллическая μ-модификация 1-[(3R)-3-[4-амино-3-(4-фенокси-фенил)-1Н-пиразоло[3,4-d]пиримидин-1-ил]-1-пиперидил]-2-пропенил-1-она, способ её получения и фармацевтическая композиция на её основе |
CA3100146A1 (en) | 2018-06-15 | 2019-12-19 | Janssen Pharmaceutica Nv | Formulations/compositions comprising ibrutinib |
US11878967B2 (en) | 2018-06-19 | 2024-01-23 | Merck Patent Gmbh | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain |
CN108727387B (zh) * | 2018-07-25 | 2021-03-16 | 天津大学 | 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法 |
US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
CN110804058B (zh) * | 2018-08-06 | 2022-11-11 | 鲁南制药集团股份有限公司 | 一种伊布替尼新晶型及其制备方法 |
CN111138436A (zh) * | 2018-11-04 | 2020-05-12 | 鲁南制药集团股份有限公司 | 伊布替尼晶型a单晶及其制备方法 |
AU2019387497A1 (en) | 2018-11-30 | 2021-06-24 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
JP2022513689A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法におけるb細胞悪性腫瘍の投与および処置のための方法 |
EP3890723A4 (en) * | 2018-12-06 | 2022-08-03 | Arthrosi Therapeutics, Inc. | CRYSTALLINE FORMS OF A COMPOUND USED TO TREAT OR PREVENT GOUT OR HYPERURICEMIA |
US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
EP3669867A1 (en) | 2018-12-21 | 2020-06-24 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CN115398231A (zh) | 2019-12-06 | 2022-11-25 | 朱诺治疗学股份有限公司 | 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法 |
CN113135917A (zh) * | 2020-01-16 | 2021-07-20 | 北京赛思源生物医药技术有限公司 | 一种依鲁替尼的无定型物及其药用组合物 |
CN113214261A (zh) * | 2020-01-21 | 2021-08-06 | 尚科生物医药(上海)有限公司 | 一种依鲁替尼晶型a的纯化方法 |
US20230320990A1 (en) | 2020-08-28 | 2023-10-12 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
EP4281454A1 (en) | 2021-01-21 | 2023-11-29 | Synthon B.V. | Process for making ibrutinib |
WO2022260667A1 (en) | 2021-06-10 | 2022-12-15 | Hikma Pharmaceuticals Usa Inc. | Oral dosage forms of ibrutinib |
US11433072B1 (en) | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (197)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1006596A (en) | 1909-05-20 | 1911-10-24 | Kansas City Feed Company Ltd | Alfalfa-mill. |
US1008594A (en) | 1910-12-17 | 1911-11-14 | Arthur Graham France | Advertising device. |
US1010536A (en) | 1911-05-01 | 1911-12-05 | John B Turbeville | Cook-stove. |
US1010654A (en) | 1911-06-20 | 1911-12-05 | Albert F Madden | Cyclometer. |
JPS5841998B2 (ja) | 1980-07-28 | 1983-09-16 | 株式会社日立製作所 | 核燃料掴み装置 |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
DE3303707A1 (de) | 1983-02-04 | 1984-08-09 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
JPH01167840A (ja) | 1987-12-24 | 1989-07-03 | Konica Corp | 新規な写真用シアンカプラー |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO1992018106A1 (en) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Method of manufacturing solid dispersion |
AU661080B2 (en) | 1991-11-22 | 1995-07-13 | Warner Chilcott Company, Llc | Risedronate delayed-release compositions |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
WO1994008568A1 (en) | 1992-10-16 | 1994-04-28 | Nippon Shinyaku Co., Ltd. | Method of manufacturing wax matrices |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
HUP0001507A3 (en) | 1997-03-19 | 2002-01-28 | Abbott Gmbh & Co Kg | Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them |
PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
TR200001880T2 (tr) | 1997-12-31 | 2000-11-21 | Choongwae Pharma Corporation | İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi. |
ATE269295T1 (de) | 1998-04-17 | 2004-07-15 | Parker Hughes Inst | Btk inhibitoren und verfahren zur identifizierung und verwendung |
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
US20050287596A9 (en) | 1998-06-26 | 2005-12-29 | Braisted Andrew C | Novel ligands and libraries of ligands |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6998233B2 (en) | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
EP1027886B1 (en) | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
DK1212327T3 (da) | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
JP5036112B2 (ja) | 1999-10-06 | 2012-09-26 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | チロシンキナーゼのインヒビターとして有益な複素環化合物 |
CA2390857A1 (en) | 1999-11-30 | 2001-06-14 | Fatih M. Uckun | Inhibitors of collagen-induced platelet aggregation |
CA2394650A1 (en) | 1999-12-17 | 2001-06-21 | Chi B. Vu | Novel heterocycles |
GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
GB0108903D0 (en) | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
JP2004533209A (ja) | 2000-10-23 | 2004-11-04 | ブリストル−マイヤーズ スクイブ カンパニー | ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用 |
US20030035833A1 (en) * | 2000-12-06 | 2003-02-20 | Xiaorong He | Rapidly dispersing pharmaceutical composition |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US8306897B2 (en) | 2001-05-04 | 2012-11-06 | Stockshield, Inc. | Method and system for insuring against investment loss |
WO2003000187A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
US20030119060A1 (en) | 2001-08-10 | 2003-06-26 | Desrosiers Peter J. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
EP1418917A1 (en) | 2001-08-10 | 2004-05-19 | Novartis AG | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
CA2464094C (en) | 2001-11-21 | 2013-07-02 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
GB2388594A (en) | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
US7687506B2 (en) | 2003-04-11 | 2010-03-30 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
US8131475B2 (en) | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
WO2005024043A2 (en) | 2003-09-03 | 2005-03-17 | Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
KR100872204B1 (ko) | 2003-10-15 | 2008-12-09 | 오에스아이 파마슈티컬스, 인코포레이티드 | 이미다조피라진 티로신 키나제 억제제 |
WO2005060956A1 (en) | 2003-12-12 | 2005-07-07 | University Of Maryland, Baltimore | IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN |
BRPI0418031A (pt) | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
US20050153990A1 (en) | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
MXPA06007829A (es) | 2004-01-08 | 2006-09-01 | Wyeth Corp | Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico. |
CN1934113B (zh) | 2004-01-26 | 2011-11-09 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的组合物 |
JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
ITMI20041314A1 (it) | 2004-06-30 | 2004-09-30 | Nuvera Fuel Cells Europ Srl | Dispositivo di raffreddamento per celle a combustibili a membrana |
MY139689A (en) | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
WO2006036941A2 (en) | 2004-09-27 | 2006-04-06 | Kosan Biosciences Incorporated | Specific kinase inhibitors |
CN101065374A (zh) | 2004-09-28 | 2007-10-31 | 詹森药业有限公司 | 取代的二哌啶化学引诱物细胞因子受体2拮抗剂 |
US20060178367A1 (en) | 2004-11-10 | 2006-08-10 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
CA2601955C (en) * | 2005-03-07 | 2012-07-10 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
BRPI0608252A2 (pt) | 2005-03-10 | 2010-04-06 | Cgi Pharmaceuticals Inc | entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas |
GT200600197A (es) | 2005-05-13 | 2007-03-28 | Compuestos y composiciones como inhibidores de proteina quinasa | |
CA2609353C (en) | 2005-05-23 | 2015-04-28 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
US7863288B2 (en) | 2005-06-22 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2007021966A1 (en) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate hsp90 activity |
US20070065449A1 (en) | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
JP2009515879A (ja) | 2005-11-12 | 2009-04-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tecキナーゼ阻害剤 |
WO2007087068A2 (en) | 2006-01-13 | 2007-08-02 | Pharmacyclics, Inc. | Inhibitors of tyrosine kinases and uses thereof |
ES2420834T3 (es) | 2006-01-30 | 2013-08-27 | The Scripps Research Institute | Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero |
TW200812611A (en) | 2006-03-20 | 2008-03-16 | Vertex Pharma | Pharmaceutical compositions |
GB2453058A (en) | 2006-04-04 | 2009-03-25 | Univ California | Kinase antagonists |
EP2865381A1 (en) | 2006-05-18 | 2015-04-29 | Pharmacyclics, Inc. | ITK inhibitors for treating blood cell malignancies |
DE102006026583A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
CN101610676B (zh) | 2006-09-22 | 2013-03-27 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
WO2008054827A2 (en) | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
FI20080352A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi |
EP2051702A1 (en) | 2007-01-22 | 2009-04-29 | Novavax, Inc. | Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability |
NL2000640C2 (nl) * | 2007-03-05 | 2008-09-08 | Stichting Wetsus Ct Of Excelle | Werkwijze en systeem voor het zuiveren van een vloeistof. |
KR101425248B1 (ko) | 2007-03-28 | 2014-08-06 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제의 억제제 |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20090010911A1 (en) | 2007-04-06 | 2009-01-08 | Iowa State University Research Foundation, Inc. | Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities |
PL2142529T3 (pl) | 2007-04-27 | 2014-06-30 | Purdue Pharma Lp | Antagoniści trpv1 i ich zastosowania |
AP2817A (en) * | 2007-07-30 | 2013-12-31 | Ardea Biosciences Inc | Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same |
US7982036B2 (en) | 2007-10-19 | 2011-07-19 | Avila Therapeutics, Inc. | 4,6-disubstitued pyrimidines useful as kinase inhibitors |
JP5587193B2 (ja) | 2007-10-23 | 2014-09-10 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なキナーゼ阻害剤 |
US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
US20150152115A1 (en) | 2007-12-27 | 2015-06-04 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CA2905541C (en) | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
WO2009124982A1 (en) | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
AU2009236325A1 (en) | 2008-04-14 | 2009-10-22 | Ardea Biosciences, Inc. | Compositions and methods for preparing and using same |
EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
CA2727455C (en) | 2008-06-27 | 2019-02-12 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
WO2010009342A2 (en) | 2008-07-16 | 2010-01-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
WO2010014728A1 (en) | 2008-07-29 | 2010-02-04 | Frontier Scientific Inc. | Use of tetrakis (n-alkylpyridinium) -porphyrin derivatives for killing microbes or preventing growth |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
JP5656976B2 (ja) | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
RU2012114902A (ru) | 2009-09-16 | 2013-10-27 | Авила Терапьютикс, Инк. | Конъюгаты и ингибиторы протеинкиназы |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
DK2578585T3 (en) | 2010-05-31 | 2016-11-14 | Ono Pharmaceutical Co | PURINONDERIVAT AS BTK kinase inhibitor |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
NZ702485A (en) | 2010-06-03 | 2016-04-29 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
NZ627709A (en) | 2010-06-23 | 2014-12-24 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
MX336875B (es) | 2010-08-10 | 2016-02-04 | Celgene Avilomics Res Inc | Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk). |
BR112013003097B1 (pt) | 2010-08-12 | 2021-03-16 | Boehringer Ingelheim International Gmbh | 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica |
US8541391B2 (en) | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
US8501484B2 (en) | 2011-03-14 | 2013-08-06 | Los Alamos National Security, Llc | Preparation of cerium halide solvate complexes |
MX2011004759A (es) | 2011-05-04 | 2012-11-21 | Senosiain S A De C V Lab | Nuevas formas solidas de antibioticos. |
WO2012158764A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CN103813794A (zh) | 2011-07-18 | 2014-05-21 | 拓凯制药公司 | 用于治疗***癌的新型组合物及方法 |
MY179332A (en) | 2011-09-02 | 2020-11-04 | Incyte Holdings Corp | Heterocyclylamines as pl3k inhibitors |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
CN104159574A (zh) | 2012-01-13 | 2014-11-19 | X喷雾微粒公司 | 用于生产包含至少一种蛋白激酶抑制剂和至少一种聚合物稳定与基质形成组分的稳定的、无定形杂化纳米颗粒的方法 |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
JP5514256B2 (ja) | 2012-05-18 | 2014-06-04 | 株式会社東芝 | 磁気記憶素子及びその製造方法 |
CA2991994C (en) | 2012-06-04 | 2022-06-28 | Pharmacyclics Llc | Pharmaceutical formulation for oral administration comprising ibrutinib |
KR102150432B1 (ko) | 2012-06-18 | 2020-09-01 | 프린시피아 바이오파마, 인코퍼레이티드 | 암 및 자가면역 질환 치료에 유용한 가역적인 공유 피롤로- 또는 피라졸로피리미딘 |
US20150140085A1 (en) | 2012-06-29 | 2015-05-21 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
CN103121999A (zh) | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
CA2890934A1 (en) | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
AU2014251028A1 (en) | 2013-04-08 | 2015-11-05 | Janssen Pharmaceutica Nv | Ibrutinib combination therapy |
EP3811974A1 (en) | 2013-05-30 | 2021-04-28 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
US20160067241A1 (en) * | 2013-06-13 | 2016-03-10 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
EP3027192A4 (en) | 2013-08-02 | 2017-03-22 | Pharmacyclics, LLC | Methods for the treatment of solid tumors |
ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
US10253244B2 (en) | 2013-09-04 | 2019-04-09 | Halliburton Energy Services, Inc. | Scale-inhibiting cocrystals for treatment of a subterranean formation |
EP3044338B1 (en) | 2013-09-12 | 2021-11-24 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
CN104447701B (zh) | 2013-09-17 | 2019-03-22 | 广东东阳光药业有限公司 | 吡唑类衍生物及其用途 |
WO2015061752A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
EP4115886A1 (en) | 2013-10-25 | 2023-01-11 | Pharmacyclics LLC | Methods of treating and preventing graft versus host disease |
WO2015071432A1 (en) | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
CN103694241A (zh) * | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
AU2014360758B2 (en) | 2013-12-02 | 2020-03-26 | Pharmacyclics Llc | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
US9260415B2 (en) | 2013-12-05 | 2016-02-16 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
CA2933900A1 (en) | 2013-12-20 | 2015-06-25 | Georgia Tech Research Corporation | Formulations and methods for targeted ocular delivery of therapeutic agents |
CN106008516A (zh) | 2014-01-29 | 2016-10-12 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
EP3102190A4 (en) | 2014-02-07 | 2017-09-06 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
US20150231077A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
WO2015127261A1 (en) | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarkers for predicting response of dlbcl to treatment with ibrutinib |
US20150267752A1 (en) | 2014-03-19 | 2015-09-24 | Roller Bearing Company Of America, Inc. | Bearing outer race having a radially inwardly biased seal |
JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼcガンマ2及び耐性に関連した変異 |
AU2015237744A1 (en) | 2014-03-27 | 2016-09-15 | Wavelength Enterprises Ltd | Ibrutinib solid forms and production process therefor |
WO2015149056A1 (en) | 2014-03-28 | 2015-10-01 | Board Of Regents, The University Of Texas System | Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury |
CN105085529A (zh) | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US20150110871A1 (en) | 2014-06-02 | 2015-04-23 | David Wong | Gastric retentive tablet compositions |
US20160008777A1 (en) | 2014-07-09 | 2016-01-14 | Novotec Consulting Inc. | Pharmaceutical compounding kit |
PT107846B (pt) | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
WO2016020697A1 (en) | 2014-08-06 | 2016-02-11 | Cipla Limited | Pharmaceutical compositions of polymeric nanoparticles |
JP2017523206A (ja) | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
EP3180343A1 (en) | 2014-08-14 | 2017-06-21 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
WO2016050422A1 (en) | 2014-10-01 | 2016-04-07 | Ratiopharm Gmbh | Acid addition salt of ibrutinib |
CN104523695A (zh) | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
CN105640961A (zh) | 2014-11-18 | 2016-06-08 | 山东瑞禾医药科技有限公司 | 一种含依鲁替尼的药物组合物 |
WO2016079216A1 (en) | 2014-11-20 | 2016-05-26 | Sandoz Ag | Physical forms of ibrutinib, a bruton's kinase inhibitor |
US20150224060A1 (en) | 2015-01-03 | 2015-08-13 | David Wong | Gastric retentive tablet compositions |
CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
JP2018511580A (ja) | 2015-03-03 | 2018-04-26 | ドクター レディズ ラボラトリーズ リミテッド | イブルチニブの多形体 |
PT3265084T (pt) | 2015-03-03 | 2024-02-13 | Pharmacyclics Llc | Formulações farmacêuticas de inibidor de tirosina cinase de bruton |
MA41827A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
MA41828A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
US10377758B2 (en) | 2015-04-02 | 2019-08-13 | Ratiopharm Gmbh | Co-crystals of ibrutinib with carboxylic acids |
SG11201707989PA (en) | 2015-04-06 | 2017-10-30 | Janssen Pharmaceutica Nv | Compositions containing ibrutinib |
CN105294696A (zh) | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
CN105440040B (zh) | 2015-12-23 | 2018-03-13 | 浙江京新药业股份有限公司 | 依鲁替尼的纯化方法 |
CA3008338A1 (en) | 2016-01-19 | 2017-07-27 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
EA201891664A1 (ru) | 2016-01-19 | 2019-02-28 | Янссен Фармацевтика Нв | Составы/композиции, содержащие ингибитор btk |
CN105646499A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型g及制备方法 |
CN105646484A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 晶型b及制备方法 |
CN105646498A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型f及制备方法 |
CN106619643A (zh) | 2016-11-11 | 2017-05-10 | 上海雅本化学有限公司 | 一种含依鲁替尼的药物组合物 |
-
2013
- 2013-06-03 CA CA2991994A patent/CA2991994C/en active Active
- 2013-06-03 NZ NZ737725A patent/NZ737725A/en unknown
- 2013-06-03 US US13/908,949 patent/US9296753B2/en active Active
- 2013-06-03 SG SG11201408067YA patent/SG11201408067YA/en unknown
- 2013-06-03 SG SG10202101389TA patent/SG10202101389TA/en unknown
- 2013-06-03 WO PCT/US2013/043888 patent/WO2013184572A1/en active Application Filing
- 2013-06-03 CA CA2875986A patent/CA2875986C/en active Active
- 2013-06-03 PE PE2014002374A patent/PE20150174A1/es not_active Application Discontinuation
- 2013-06-03 KR KR1020227021197A patent/KR20220093389A/ko not_active IP Right Cessation
- 2013-06-03 US US14/405,317 patent/US9540382B2/en active Active
- 2013-06-03 KR KR1020147036843A patent/KR20150015021A/ko not_active Application Discontinuation
- 2013-06-03 MY MYPI2018000375A patent/MY194911A/en unknown
- 2013-06-03 NZ NZ731932A patent/NZ731932A/en unknown
- 2013-06-03 CN CN201380041392.XA patent/CN104736178A/zh active Pending
- 2013-06-03 EP EP13799982.7A patent/EP2854859A4/en active Pending
- 2013-06-03 TW TW107101564A patent/TWI662963B/zh active
- 2013-06-03 PE PE2019000040A patent/PE20190390A1/es unknown
- 2013-06-03 KR KR1020177021511A patent/KR20170091785A/ko active Application Filing
- 2013-06-03 UA UAA201414091A patent/UA114421C2/uk unknown
- 2013-06-03 MX MX2014014848A patent/MX348290B/es active IP Right Grant
- 2013-06-03 AU AU2013271918A patent/AU2013271918C1/en active Active
- 2013-06-03 CN CN201910730441.XA patent/CN110354132A/zh active Pending
- 2013-06-03 EA EA201492082A patent/EA201492082A1/ru unknown
- 2013-06-03 TW TW107137018A patent/TWI662964B/zh active
- 2013-06-03 CA CA3218491A patent/CA3218491A1/en active Pending
- 2013-06-03 NZ NZ702548A patent/NZ702548A/en unknown
- 2013-06-03 UA UAA201700877A patent/UA126959C2/uk unknown
- 2013-06-03 JP JP2015516091A patent/JP6236071B2/ja active Active
- 2013-06-03 MA MA41654A patent/MA41654B2/fr unknown
- 2013-06-03 KR KR1020207003793A patent/KR20200017549A/ko active Application Filing
- 2013-06-03 MA MA37711A patent/MA37711A1/fr unknown
- 2013-06-03 KR KR1020237041085A patent/KR20230170108A/ko not_active Application Discontinuation
- 2013-06-03 NZ NZ713828A patent/NZ713828A/en unknown
- 2013-06-03 CA CA3015208A patent/CA3015208C/en active Active
- 2013-06-03 JO JOP/2013/0168A patent/JO3754B1/ar active
- 2013-06-03 BR BR112014030424A patent/BR112014030424A8/pt not_active Application Discontinuation
- 2013-06-03 KR KR1020197010159A patent/KR20190040370A/ko not_active Application Discontinuation
- 2013-06-03 MY MYPI2014003370A patent/MY187999A/en unknown
- 2013-06-03 KR KR1020217007940A patent/KR20210033067A/ko not_active Application Discontinuation
- 2013-06-03 TW TW102119583A patent/TWI653041B/zh active
- 2013-06-04 UY UY0001034848A patent/UY34848A/es not_active Application Discontinuation
- 2013-06-04 UY UY0001039740A patent/UY39740A/es not_active Application Discontinuation
- 2013-06-04 AR ARP130101974A patent/AR092844A1/es unknown
-
2014
- 2014-07-23 US US14/339,363 patent/US20140336203A1/en not_active Abandoned
- 2014-11-25 IL IL235894A patent/IL235894B/en active IP Right Grant
- 2014-11-25 TN TN2014000492A patent/TN2014000492A1/fr unknown
- 2014-11-27 DO DO2014000274A patent/DOP2014000274A/es unknown
- 2014-12-01 PH PH12014502681A patent/PH12014502681A1/en unknown
- 2014-12-03 CL CL2014003306A patent/CL2014003306A1/es unknown
- 2014-12-04 CR CR20140558A patent/CR20140558A/es unknown
- 2014-12-04 GT GT201400281A patent/GT201400281A/es unknown
- 2014-12-04 MX MX2021012478A patent/MX2021012478A/es unknown
- 2014-12-16 CO CO14276324A patent/CO7240408A2/es unknown
- 2014-12-24 EC ECIEPI201433163A patent/ECSP14033163A/es unknown
-
2015
- 2015-09-25 HK HK15109505.2A patent/HK1208803A1/xx unknown
-
2016
- 2016-10-28 AU AU2016250445A patent/AU2016250445B2/en active Active
- 2016-12-21 US US15/386,118 patent/US9713617B2/en active Active
-
2017
- 2017-02-13 CL CL2017000371A patent/CL2017000371A1/es unknown
- 2017-04-26 US US15/497,896 patent/US9725455B1/en active Active
- 2017-06-22 DO DO2017000152A patent/DOP2017000152A/es unknown
- 2017-07-10 US US15/645,319 patent/US20170305919A1/en not_active Abandoned
- 2017-08-07 US US15/670,614 patent/US9828383B1/en active Active
- 2017-08-17 JP JP2017157676A patent/JP2018012710A/ja active Pending
- 2017-09-27 IL IL254739A patent/IL254739A0/en unknown
- 2017-10-26 JP JP2017207591A patent/JP2018048182A/ja active Pending
- 2017-12-29 CL CL2017003496A patent/CL2017003496A1/es unknown
-
2018
- 2018-02-02 US US15/887,712 patent/US20180170940A1/en not_active Abandoned
- 2018-02-02 US US15/887,744 patent/US20180155352A1/en not_active Abandoned
- 2018-02-20 US US15/900,660 patent/US10106548B2/en active Active
- 2018-02-21 US US15/901,118 patent/US10065968B2/en active Active
- 2018-07-13 US US16/035,449 patent/US10266540B2/en active Active
- 2018-07-16 US US16/036,207 patent/US20180319805A1/en not_active Abandoned
- 2018-07-16 US US16/036,258 patent/US10125140B1/en active Active
- 2018-07-31 AU AU2018211201A patent/AU2018211201B2/en active Active
- 2018-07-31 AU AU2018211216A patent/AU2018211216B2/en active Active
- 2018-08-23 US US16/111,014 patent/US10294232B2/en active Active
- 2018-08-23 US US16/110,999 patent/US10294231B2/en active Active
- 2018-08-23 US US16/110,969 patent/US20180362534A1/en not_active Abandoned
-
2019
- 2019-03-06 EC ECSENADI201915794A patent/ECSP19015794A/es unknown
- 2019-04-24 US US16/393,797 patent/US20190248799A1/en not_active Abandoned
- 2019-04-24 US US16/393,775 patent/US20190248798A1/en not_active Abandoned
- 2019-07-16 JP JP2019131481A patent/JP6937086B6/ja active Active
- 2019-09-06 JP JP2019163455A patent/JP2020015744A/ja active Pending
-
2020
- 2020-01-02 PH PH12020500028A patent/PH12020500028A1/en unknown
- 2020-01-15 US US16/744,007 patent/US20200148691A1/en not_active Abandoned
- 2020-02-14 AR ARP200100425A patent/AR118108A2/es unknown
- 2020-03-19 US US16/824,630 patent/US20200231595A1/en not_active Abandoned
- 2020-04-01 US US16/837,665 patent/US10752634B2/en active Active
- 2020-09-09 JO JOP/2020/0222A patent/JOP20200222A1/ar unknown
- 2020-09-24 AU AU2020239751A patent/AU2020239751B2/en active Active
- 2020-10-08 US US17/066,192 patent/US20210032258A1/en not_active Abandoned
- 2020-11-18 US US16/951,796 patent/US10961251B1/en active Active
-
2021
- 2021-04-18 IL IL282367A patent/IL282367A/en unknown
- 2021-05-24 US US17/328,644 patent/US20220112196A1/en not_active Abandoned
- 2021-07-22 ZA ZA2021/05174A patent/ZA202105174B/en unknown
- 2021-07-22 ZA ZA2021/05175A patent/ZA202105175B/en unknown
- 2021-07-26 JP JP2021121857A patent/JP2021183617A/ja active Pending
- 2021-08-24 JP JP2021136489A patent/JP2021193095A/ja active Pending
-
2022
- 2022-05-06 DO DO2022000096A patent/DOP2022000096A/es unknown
-
2023
- 2023-01-27 AU AU2023200435A patent/AU2023200435A1/en active Pending
- 2023-07-13 JP JP2023115449A patent/JP2023162162A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200222A1 (ar) | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون | |
MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
MX2021015405A (es) | Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton. | |
MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
PH12020552065A1 (en) | Ibrutinib combination therapy | |
MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
NZ702485A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
PH12015502053A1 (en) | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
MX2011009033A (es) | Inhibidores triciclicos de cinasa pirazolopiridina. | |
MX2019000159A (es) | Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa. |